Trials / Active Not Recruiting
Active Not RecruitingNCT03987958
A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
Prospective Non-interventional Study to Describe the Effectiveness and Safety of Venetoclax in Acute Myeloid Leukemia (AML) Patients in Routine Clinical Practice (REVIVE Study)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will describe the safety and effectiveness of venetoclax in AML patients in routine clinical practice in Israel. The decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study.
Conditions
Timeline
- Start date
- 2019-08-08
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2019-06-17
- Last updated
- 2026-01-16
Locations
12 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT03987958. Inclusion in this directory is not an endorsement.